CA2686566A1 - Multi-dose concentrate esmolol with benzyl alcohol - Google Patents

Multi-dose concentrate esmolol with benzyl alcohol Download PDF

Info

Publication number
CA2686566A1
CA2686566A1 CA002686566A CA2686566A CA2686566A1 CA 2686566 A1 CA2686566 A1 CA 2686566A1 CA 002686566 A CA002686566 A CA 002686566A CA 2686566 A CA2686566 A CA 2686566A CA 2686566 A1 CA2686566 A1 CA 2686566A1
Authority
CA
Canada
Prior art keywords
composition
esmolol
benzyl alcohol
buffering agent
volume
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002686566A
Other languages
French (fr)
Inventor
Deepak Tiwari
George Owoo
Rekha Nayak
Kenneth E. Burhop
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baxter Healthcare SA
Baxter International Inc
Original Assignee
Baxter International Inc.
Baxter Healthcare S.A.
Deepak Tiwari
George Owoo
Rekha Nayak
Kenneth E. Burhop
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter International Inc., Baxter Healthcare S.A., Deepak Tiwari, George Owoo, Rekha Nayak, Kenneth E. Burhop filed Critical Baxter International Inc.
Publication of CA2686566A1 publication Critical patent/CA2686566A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Disclosed are concentrate esmolol injection essentially free from other related esters of esmolol and diluted esmolol compositions. The concentrate esmolol formulation includes from about 25-1000 mg/ml of esmolol and about 1-25 % w/v of benzyl alcohol and the combination thereof. The compositions can also be used as multi-dose compositions. The present invention also discloses diluted, ready-to-use compositions of esmolol prepared by dilution of the present invention concentrates. Also disclosed are methods of making and using the ready-to-use compositions of the present invention.

Description

MULTI-DOSE CONCENTRATE ESMOLOL WITH BENZYL ALCOHOL
BACKGROUND OF THE INVENTION
[0001] The present invention is directed to enhanced stability concentrate esmolol formulations. More specifically, the invention is directed to a concentrate esmolol formulation stabilized with benzyl alcohol. The compositions of the present invention are also suitable as multiple-dose compositions. Additionally, the present invention is directed to ready-to-use, diluted compositions made by dilution of the concentrate esmolol compositions of the present invention.
[0002] Esmolol (and its pharmaceutically acceptable salts, e.g., hydrochloride salt) and related compounds have {i-adrenergic blocking activity. 0-blockers are therapeutically effective agents for the treatment and prophylaxis of cardiac disorders when administered in the appropriate dosage. Esmolol, which is a short-acting 0-blocker, is often times used in acute care settings to control the heart rate of a patient. The short acting property of esmolol is due to its rapid hydrolysis of the labile aliphatic methyl ester group in the blood.
[00033 Ready-to-use isotonic, and concentrate formulations, of esmolol are disclosed in U.S. Patent Nos. 5,017,609, 6,310,094, and 6,528,540, incorporated herein by reference.
Methods for making esmolol and methods for treatment or prophylaxis of cardiac disorders using such compounds are disclosed in U.S. Patent 4,387,103, and 4,593,119, incorporated herein by reference. A current commercial esmolol concentrate formulation, covered under U.S. Patent No. 5,017,609, comprises about 250 mglml of esmolol hydrochloride, 25% by volume ethanol, 25% by volume propylene glycol, 17 mg/mI sodium acetate trihydrate, and 0.715% by volume of glacial acetic acid. This composition is not intended for direct injection but for subsequent dihition with a suitable diluent.
[00043 The stability of esmolol hydrochloride { methyl 3-[4-[2-hydoxy-3-(isopropylamino)propoxy]phenyl]propionate hydrochloride) in water is mediated by the rate of acid/base catalyzed hydrolysis of the labile aliphatic methyl ester group and it degrades into ASL-8123 {methyl 3-[4-[2-hydoxy-3-(isopropylamino) propoxy]phenyl,]propionic acid).
Ready-to-use isotonic formulations address some of the stability issues in a truly aqueous formulation and has only one degradant, ASL-8123. The current commercial concentrate formulation employs excipients (ethanol and propylene glycol) to stabilize the hydrolytic reaction, but those excipients leads to the formation of other related ester degradants.

Therefore, the current commercial esmolol concentrate formulation under long term storage conditions results in the formation of ethyl and propoyl esters of esmolol in addition to ASL-8123. Furthermore the excipients (ethanol and propylene glycol) used to stabilize the current cominercial esmolol concentrate formulation have been associated with potential injection site pain or irritation.
[0005] Therefore, it would be desirable to provide a stabilized concentrate esmolol composition that eliminates the formation of related ester degradants, does not include potentially irritating propylene glycol and ethanol excipients, is simpler to make than the prior art concentrate composition and, optionally, can be preserved rendering it applicable for multiple-dose use.

SUMMARY OF THE INVENTION
[00063 In one aspect of the present invention, a concentrate esmolol formulation is provided. The concentrate esmolol formulation comprises about 25-1000 mg/mi of esmolol (or pharmaceutically acceptable salts thereof), about 1 to 25 % by volume of benzyl alcohol and, optionally, from about 0.005 to about 2 molar (M) of a buffering agent.
The compositions are pH adjusted to between about 3.5 and about 7Ø Benzyl alcohol, typically used as a preservative, has been surprisingly found to stabilize the concentrate esmolol compositions of the present invention.
[00071 In. another aspect of the present invention a ready-to-use composition and a method of dosing such composition is provided. The method comprises the steps of providing a concentrate esmolol formulation of about 25-1000 mg/ml of esmolol (or a pharmaceutically acceptable salt thereof) and 1-25 % weight/volume benzyl alcohol, selecting a volume from the liquid for further dilution with a suitable diluent, followed by injection of the diluted product to the patient.
[0008] An advantage of the present invention is that, unlike prior art concentrate compositions of esmolol, the formulation does not form degredants of other related esters of esmolol.
[0009] Another advantage of the present invention is that it offers the flexibility of multiple-dose use of the formulation without microbial cross-contamination.
[00101 Another advantage of the present invention is that it reduces the potential of injection site pain/irritation contributed by propylene glycol and ethanol excipients.
[0011] Still another advantage of the present invention is that it provides sterile, concentrate esmolol compositions that contain less excipients and are simpler to make than prior art concentrates.

BRIEF DESCRITPION OF THE DRAWING
(00121 FIG. I is a chemical scheme depicting the transecterification of esmolol in the presence of ethanol and propylene glycol to yield respective esters.

DETAILED DESCRIPTION OF THE INVENTION
[ 0013 ] The compositions of the present invention comprise esmolol, or pharmaceutically acceptable salts thereof, e.g., hydrochloride, and benzyl alcohol. As used herein, "esmolol"
refers to esmolol free base and pharmaceutically acceptable salts thereof. The concentration of esmolol in the concentrate ranges from about 25-1000 mg/ml, and preferably is about 250 mg/ml.
[00141 As stated above, the main degradation pathway for esmolol is the hydrolysis of its aliphatic carboxy niethyl ester moiety to yield ASL-8123. This degradation depends on the pH, buffer concentrations and concentration of esmolol. The current commercial esmolol concentrate formulation is stabilized by the presence of ethanol and propylene glycol.
However, the historical stability data indicate that esmolol in the presence of these solvents undergoes transesterification reactions to yield ethyl and propylene glycol esters of esmolol.
(See Figure 1.) [00151 The compositions of the present invention contain an amount of benzyl alcohol to stabilize the esmolol concentrate compositions. Although benzy] alcohol. is typically used as a preservative, it has surprisingly been found to stabilize concentrate esmolol compositions of the present invention. In. general, the amount of benzyl alcohol present will depend on the concentration of esmolol present. A typical range of benzyl alcohol in the compositions will be from about 1 to 25 % weight/volume (w/v). Preferably, for esmolol concentrations of 250 mg/ml, benzyl alcohol will be present in a concentration of about 10 % w/v.
[0016] The concentrate of present invention can also include a pharmaceutically acceptable buffer to aid in maintaining the pH in a range of from about 3.5 to about 7Ø
Preferably, the pH is maintained between about 4.5 and about 5.5, more preferably between 4.9 and 5.1. Degradation of esmolol occurs most rapidly when the pH is outside the range of 4.0 to 6.0 and is most stable around a pH of about 5Ø Suitable buffers are those buffers that provide sufficient buffering capacity at the desired pH range and are pharmacetttically acceptable for injection into a patient. Examples of buffers useful in the present invention include, but are not limited to, acetate, glutamate, citrate, tartrate, benzoate, lactate, gluconate, phosphate and glycine and conjugate acids thereof. The concentration of the buffer can be from about 0.005 to about 2 M. In a preferred embodiment, the buffering agent comprises a combination of sodium acetate and glacial acetic acid. A preferred combination of buffers can include sodium acetate at from about 0.005 to about 0.3 M and glacial acetic acid at from about 0.05 to about 0.3 M.
[0017] Suitable containers for housing the esmolol concentrate are known in the art.
They include vial, syringe and ampoule presentations. Containers may be fabricated of polymeric materials or from glass. Preferred polymeric containers are free of polyvinylchlorine (PVC). Preferably, the container has excellent barrier properties. A
preferred container retains a moisture barrier such as glass containers or polymeric containers including barrier layers or secondary packaging. An aluminum overpouch is a preferred inoisture barrier for use as secondary packaging for polymeric containers lacking a moisture barrier of their own. Preferred containers should be able to withstand terminal sterilization such as autoclaving.
[0018] The compositions of the present invention are sterile. The compositions are preferably prepared and then sterilized in their final containers by autoclaving. Alternatively, the concentrate can be aseptically prepared or terminally sterilized via autoclaving separately and then placed in sterile containers using an aseptic procedure. Typical autoclave cycles used in the pharmaceutical industry to achieve terminal sterilization of the final product are 121 C for 15 minutes. The esmolol concentrate of the present invention can be autoclaved at a temperature ranging from 115 to 130 'C for a period of time ranging from about 5 to 40 minutes with acceptable stability. Autoclaving is preferably carried out in the temperature range of about 119 to 122 C for a period of time ranging from about 10 to 36 minutes.
[00191 In one embodiment the concentrate is housed in a clear glass or plastic syringe and terminally sterilized. These pre-filled syringes can be provided in various volumes to permit quick and easy preparation of either small volume or large volume parental dosage by dispensing the contents of the pre-filled syringes into standard or customized, pre-filled intravenous fluid bags.

(00201 In another embodiment, the concentrate esmolol compositions of the present invention are packaged in sealed vials, preferably of type I treated glass.
[0021] The present invention is also directed to diluted, esmolol conipositions made with the esmolol concetitrates of the present invention. A practitioner can make a diluted concentration of esmolol with the use of a preferred diluent for infusion into the patient.
Suitable diluents include diluents used by practitioners skilled in the art.
Typical examples include but are not limited to, sodium chloride solutions, Ringers' or dextrose solutions.
While the desired, diluted concentration of esmolol will vary depending on need, typical concentrations range from about 5 to about 25 mg/ml, and preferably 10 mg/ml of esmolol.
[0022] Suitable routes of administration for the diluted compositions of the present invention include intravenous, subcutaneous, intradermal, intramuscular, intraarticular, and intrathecal. The diluted composition is preferably administered by intravenous infusion.
(00231 The following example compositions and method of manufacture further illustrate the invention but should not be construed as limiting its scope.

Example 1 (00241 The following describes the preparation of esmolol concentrate containing 250 mg/mL of esinolol HCI and benzyl alcohol. The concentration of each ingredient of the composition is as follows:

In redient Concentration Esmolol 250 m mL
Sodium Acetate Trihydrate l7mg/mL
Glacial Acetic Acid 0.00715mIJmL
Benzyl Alcohol, USP 10% w/v Water for Injection, USP Qs The equipment and glassware for compounding, filtering, and filling are properly washed and depyrogenated. The filter assembly, filling tube assembly, and other parts and equipment are sterilized. Eighty percent (80%) of the final volume of cool water for injection is collected in a compounding tank. Glacial acetic acid and sodium acetate are then added to the tank.
Esmolol hydrochloride is weighed and added to the tank. Required quantity of the benzyl alcohol is weighed and added to the tank. The solution is stirred until all excipients are dissolved. The solution is then adjusted to pH 5.0 with sodium hydroxide or hydrochloric acid. The solution is brought to final volume with water for injection and mixed. The solution is filled in 10-mL type I treated flint ampoules and sealed. The product is the sterilized at 122 C for 20 minutes.
Example 2 [0025) The stability of esmolol hydrochloride at 55 C in water or water-benzyl alcohol solution is summarized in Tables I and 2, respectively. The stability of the formulation of Example I at 55 C in water is summarized in Table 3. As demonstrated by the data, the presence of benzyl alcohol greatly reduced the degradation of esmolol (Table 2). And the degradation of esmolol was further reduced when benzyl alcohol is utilized along with the buffer to maintain the pH at 5.0 (Table 3). The absence of propoyl ester degradants peak (at approximate relative retention times of 0.55 and 0.60 - from an HPLC
chromatogram) and ethyl ester degradant peak (at approximate relative retention times of 2.10), indicate that the present invention does not contain any of the degradants seen in the prior art current commercial esmolol concentrate formulation. Replacing ethanol and propylene glycol with benzyl alcohol eliminates the transesterification reaction and the formation of ethyl and propylene glycol ester degradants of esmolol, thereby improving the stability and safety profile of the prior art concentrate formulation.

Table 1. Stability of 250 mg/mL Esmolol HCL in water at 55 C
Time Point pH Assay %ASL-8123 Degradants*
Initial 3.86 101.2 N.D N.D

I Week 3.33 87.1 33.8 N.D
2 Weeks 2.43 54.7 45.7 N.D
3 Weeks . 2.30 26.7 71.7 N.D
4 Weeks 2.24 14.9 80.7 N.D
*at RRT = 0.55, 0.60 and 2.10 Table 2. Stability of 250 mg/mL Esmolol HCL with 10% Benzyl Alcohol in water at 55 C
%
Time Point pH Assay %ASL-8123 Degradants*

Initial 3.89 100.7 N.D N.D
1 Week 3.33 97.1 10.2 N.D
2 Weeks 2.43 82.9 16.3 N.D
3 Weeks 2.30 67.3 31.4 N.D
4 Weeks 2.24 47.0 50.7 N.D
*at RRT = 0.55,0.60 and 2.10 Table 3. Stability of 250 mg/mL Esmolol HCL with 10% Benzyl Alcohol in buffered water at 55 C

Time %
Point pH Assay %ASL-8123 Degradants*
Initial 4.60 106.9 1.24 N.D

1 Week 4.60 101.2 2.70 N.D
4 Weeks 4.60 95.5 9.61 N.D
*at RRT = 0.55, 0.60 and 2.10 Although the present invention has been described by reference to certain preferred embodiments, it should be understood that the preferred embodiments are merely illustrative of the principles of the present invention. Therefore, modifications and/or changes may be made by those skilled in the art without departing from the true spirit and scope of the invention as defined by the appended claims.

Claims (19)

1. A concentrate esmolol composition comprising:
a) about 25-1000 mg/ml of esmolol; and b) from about 1-25% w/v of benzyl alcohol;
wherein the composition has a pH of about 3 and 7.
2. The composition of claim 1, further comprising a buffering agent.
3. The composition of claim 2, wherein the buffering agent comprises at least one of acetate, glutamate, citrate, tartrate, benzoate, lactate, gluconate, phosphate and glycine and conjugate acids thereof.
4. The composition of claim 3, wherein the buffering agent comprises sodium acetate and acetic acid.
5. The composition of claim 2, wherein the buffering agent is present in an amount of from about 0.005 to 2 M.
6. The composition of claim 1 comprising:
a) about 250 mg/mL esmolol;

b) about 10 % w/v of benzyl alcohol; and c) about 0.1 M acetate.
7. The composition of claim 1 comprising:
a) about 50 mg/mL esmolol;

b) about 2 % w/v benzyl alcohol;
c) about 0.1 M acetate .
8. A ready-to-use composition comprising esmolol made by the process of:

a) providing a volume of a first composition comprising about 25-1000 mg/ml of esmolol, and from about 1-25% w/v benzyl alcohol, wherein the first composition has a pH of about 3 to 7; and b) diluting the volume of the first composition with a volume of a second composition, the second composition comprising a pharmaceutically acceptable diluent for parenteral administration.
9. The composition of claim 8, wherein the first composition further comprises a buffering agent.
10. The composition of claim 9, wherein the buffering agent comprises at least one of acetate, glutamate, citrate, tartrate, benzoate, lactate, gluconate, phosphate and glycine and conjugate acids thereof.
11. The composition of claim 10, wherein the buffering agent comprises sodium acetate and acetic acid.
12. The composition of claim 9, wherein the buffering agent is present in an amount of from about 0.005 to 2 M.
13. The composition of claim 8, wherein the second composition is selected from the group consisting of: phosphate buffered saline, saline, Ringers' solution and dextrose solutions.
14. A method of dosing a patient with an esmolol composition comprising the steps of:

a) providing a volume of a first composition comprising about 25-1000 mg/ml of esmolol, and from about 1-25% w/v benzyl alcohol, wherein the first composition has a pH of about 3 to 7;

b) diluting the volume of the first composition with a volume of a second composition, the second composition comprising a pharmaceutically acceptable diluent for parenteral administration, to form a ready-to-use composition;

c) selecting a volume of the ready-to-use composition; and d) dosing a patient with the volume of ready-to-use composition.
15. The method of claim 14, wherein the first composition further comprises a buffering agent.
16. The method of claim 15, wherein the buffering agent is present in a concentration of from about 0.005 to 2 M.
17. The method of claim 19, wherein the buffering agent comprises sodium acetate and acetic acid.
18. The method of claim 15, wherein the first composition comprises:

a) about 250 mg/mL esmolol;

b) about 10 % w/v of benzyl alcohol; and c) about 0.1 M acetate.
19. The method of claim 15, wherein the first composition comprises about 0.1 M acetate:

a) about 50 mg/mL esmolol;

b) about 2 % w/v benzyl alcohol; and c) about 50 mg/mL esmolol.
CA002686566A 2007-05-22 2008-05-15 Multi-dose concentrate esmolol with benzyl alcohol Abandoned CA2686566A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/752,103 2007-05-22
US11/752,103 US8722736B2 (en) 2007-05-22 2007-05-22 Multi-dose concentrate esmolol with benzyl alcohol
PCT/US2008/063755 WO2008147715A2 (en) 2007-05-22 2008-05-15 Multi-dose concentrate esmolol with benzyl alcohol

Publications (1)

Publication Number Publication Date
CA2686566A1 true CA2686566A1 (en) 2008-12-04

Family

ID=40072995

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002686566A Abandoned CA2686566A1 (en) 2007-05-22 2008-05-15 Multi-dose concentrate esmolol with benzyl alcohol

Country Status (10)

Country Link
US (1) US8722736B2 (en)
EP (1) EP2164464A2 (en)
JP (1) JP2010528025A (en)
KR (1) KR20100022992A (en)
CN (1) CN101677943B (en)
AU (1) AU2008256949B2 (en)
BR (1) BRPI0811850A2 (en)
CA (1) CA2686566A1 (en)
MX (1) MX2009012614A (en)
WO (1) WO2008147715A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100311738A1 (en) 2007-12-21 2010-12-09 Aop Orphan Pharmaceuticals Ag Pharmaceutical Composition For The Parenteral Administration Of Ultrashort-Effective Beta-Adrenoreceptor Antagonists
CA2775317C (en) 2009-09-22 2014-10-28 Vlife Sciences Technologies Pvt. Ltd. Topical formulation for diabetic foot ulcers

Family Cites Families (221)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2525071A (en) 1945-11-30 1950-10-10 Standard Oil Dev Co Laminated sheet material and compositions
BE515475A (en) 1951-11-13
US2745785A (en) 1952-10-29 1956-05-15 American Home Prod Therapeutic composition comprising tabular nu, nu'-dibenzylethylenediamine di-penicillin, and process for preparing same
US3685261A (en) 1971-02-16 1972-08-22 Environeering Wet scrubber for contaminated gas
US4798846A (en) 1974-03-28 1989-01-17 Imperial Chemical Industries Plc Pharmaceutical compositions
GB1472793A (en) 1974-03-28 1977-05-04 Ici Ltd Pharmaceutical compositions
US4073943A (en) 1974-09-11 1978-02-14 Apoteksvarucentralen Vitrum Ab Method of enhancing the administration of pharmalogically active agents
JPS597693B2 (en) 1978-01-07 1984-02-20 株式会社ミドリ十字 Antithrombin preparation and its manufacturing method
DE3013839A1 (en) 1979-04-13 1980-10-30 Freunt Ind Co Ltd METHOD FOR PRODUCING AN ACTIVATED PHARMACEUTICAL COMPOSITION
US4593119A (en) 1980-11-28 1986-06-03 American Hospital Supply Corporation Method for treatment or prophylaxis of cardiac disorders
US4387103A (en) 1980-11-28 1983-06-07 American Hospital Supply Corporation Method for treatment or prophylaxis of cardiac disorders
US4725442A (en) 1983-06-17 1988-02-16 Haynes Duncan H Microdroplets of water-insoluble drugs and injectable formulations containing same
US4622219A (en) 1983-06-17 1986-11-11 Haynes Duncan H Method of inducing local anesthesia using microdroplets of a general anesthetic
US4608278A (en) 1983-06-22 1986-08-26 The Ohio State University Research Foundation Small particule formation and encapsulation
WO1985004580A1 (en) 1984-04-09 1985-10-24 American Hospital Supply Corporation Pharmaceutical composition and method for treatment or prophylaxis of cardiac disorders
US4826689A (en) 1984-05-21 1989-05-02 University Of Rochester Method for making uniformly sized particles from water-insoluble organic compounds
CA1282405C (en) 1984-05-21 1991-04-02 Michael R. Violante Method for making uniformly sized particles from water-insoluble organic compounds
US4606940A (en) 1984-12-21 1986-08-19 The Ohio State University Research Foundation Small particle formation and encapsulation
US5354563A (en) 1985-07-15 1994-10-11 Research Development Corp. Of Japan Water dispersion containing ultrafine particles of organic compounds
US5023271A (en) 1985-08-13 1991-06-11 California Biotechnology Inc. Pharmaceutical microemulsions
US5171566A (en) 1986-05-16 1992-12-15 The Green Cross Corporation Flurbiprofen derivative ophthalmic preparation
GB8618846D0 (en) 1986-08-01 1986-09-10 Smithkline Beckman Corp Chemical process
CA1338736C (en) 1986-12-05 1996-11-26 Roger Baurain Microcrystals containing an active ingredient with affinity for phospholipids and at least one phospholipid; process for preparing the same
FR2634397B2 (en) 1986-12-31 1991-04-19 Centre Nat Rech Scient PROCESS FOR THE PREPARATION OF DISPERSIBLE COLLOIDAL SYSTEMS OF A PROTEIN IN THE FORM OF NANOPARTICLES
FR2608942B1 (en) 1986-12-31 1991-01-11 Centre Nat Rech Scient PROCESS FOR THE PREPARATION OF COLLOIDAL DISPERSIBLE SYSTEMS OF A SUBSTANCE, IN THE FORM OF NANOCAPSULES
US5174930A (en) 1986-12-31 1992-12-29 Centre National De La Recherche Scientifique (Cnrs) Process for the preparation of dispersible colloidal systems of amphiphilic lipids in the form of oligolamellar liposomes of submicron dimensions
FR2608988B1 (en) 1986-12-31 1991-01-11 Centre Nat Rech Scient PROCESS FOR THE PREPARATION OF COLLOIDAL DISPERSIBLE SYSTEMS OF A SUBSTANCE, IN THE FORM OF NANOPARTICLES
IL86211A (en) 1987-05-04 1992-03-29 Ciba Geigy Ag Oral forms of administration for carbamazepine in the forms of stable aqueous suspension with delayed release and their preparation
GB8901254D0 (en) 1989-01-20 1989-03-15 Allied Colloids Ltd Particulate materials and their production
FR2631826B1 (en) 1988-05-27 1992-06-19 Centre Nat Rech Scient PARTICULATE VECTOR USEFUL IN PARTICULAR FOR THE TRANSPORT OF BIOLOGICALLY ACTIVATED MOLECULES AND METHOD FOR THE PREPARATION THEREOF
CA1340241C (en) 1988-06-08 1998-12-15 Fountain Pharmaceuticals, Inc. Method for marking solvent dilution microcarriers
US5269979A (en) 1988-06-08 1993-12-14 Fountain Pharmaceuticals, Inc. Method for making solvent dilution microcarriers
US4857552A (en) * 1988-06-08 1989-08-15 E. I. Du Pont De Nemours And Co. Stable pharmaceutical composition
EP0349428B1 (en) 1988-06-30 1993-01-20 Centre National De La Recherche Scientifique (Cnrs) Process for preparing colloidal dispersive protein systems in the shape of nanoparticles
US5707634A (en) 1988-10-05 1998-01-13 Pharmacia & Upjohn Company Finely divided solid crystalline powders via precipitation into an anti-solvent
US5474989A (en) 1988-11-11 1995-12-12 Kurita Water Industries, Ltd. Drug composition
IL92344A0 (en) 1989-01-04 1990-07-26 Gist Brocades Nv Microencapsulation of bioactive substances in biocompatible polymers,microcapsules obtained and pharmaceutical preparation comprising said microcapsules
CH677886A5 (en) 1989-06-26 1991-07-15 Hans Georg Prof Dr Weder
FR2651680B1 (en) 1989-09-14 1991-12-27 Medgenix Group Sa NOVEL PROCESS FOR THE PREPARATION OF LIPID MICROPARTICLES.
JP2602964B2 (en) 1989-10-16 1997-04-23 裕 水島 Prostaglandin analogs and their fat emulsions
US5188837A (en) 1989-11-13 1993-02-23 Nova Pharmaceutical Corporation Lipsopheres for controlled delivery of substances
US5078994A (en) 1990-04-12 1992-01-07 Eastman Kodak Company Microgel drug delivery system
US5246707A (en) 1990-04-26 1993-09-21 Haynes Duncan H Sustained release delivery of water-soluble bio-molecules and drugs using phospholipid-coated microcrystals, microdroplets and high-concentration liposomes
US5091188A (en) 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
US5091187A (en) 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
EP0461930B1 (en) 1990-06-15 1995-09-13 Merck & Co. Inc. A crystallization method to improve crystal structure and size
CA2046830C (en) 1990-07-19 1999-12-14 Patrick P. Deluca Drug delivery system involving inter-action between protein or polypeptide and hydrophobic biodegradable polymer
US5552160A (en) 1991-01-25 1996-09-03 Nanosystems L.L.C. Surface modified NSAID nanoparticles
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
AU642066B2 (en) 1991-01-25 1993-10-07 Nanosystems L.L.C. X-ray contrast compositions useful in medical imaging
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5306519A (en) 1991-05-23 1994-04-26 Universal Foods Corporation Syrup for confections and methods for using same
IT1247472B (en) 1991-05-31 1994-12-17 Fidia Spa PROCESS FOR THE PREPARATION OF MICROSPHERES CONTAINING BIOLOGICALLY ACTIVE COMPONENTS.
US5766635A (en) 1991-06-28 1998-06-16 Rhone-Poulenc Rorer S.A. Process for preparing nanoparticles
CH683149A5 (en) 1991-07-22 1994-01-31 Debio Rech Pharma Sa Process for the preparation of microspheres of a biodegradable polymeric material.
US5250236A (en) 1991-08-05 1993-10-05 Gasco Maria R Method for producing solid lipid microspheres having a narrow size distribution
CA2078388A1 (en) 1991-10-02 1993-04-03 Mridula Nair Biocompatible emulsion particles
US6063910A (en) 1991-11-14 2000-05-16 The Trustees Of Princeton University Preparation of protein microparticles by supercritical fluid precipitation
US5298483A (en) 1992-03-30 1994-03-29 Tropicana Products, Inc. New matter of composition and method for using the same as plant bioregulators
US5389263A (en) 1992-05-20 1995-02-14 Phasex Corporation Gas anti-solvent recrystallization and application for the separation and subsequent processing of RDX and HMX
JP4439590B2 (en) 1992-06-10 2010-03-24 エラン ファーマ インターナショナル，リミティド Surface modified NSAID nanoparticles
JP3961029B2 (en) 1992-06-24 2007-08-15 博 木戸 Influenza virus infection inhibitor
SE9202128D0 (en) 1992-07-09 1992-07-09 Astra Ab PRECIPITATION OF ONE OR MORE ACTIVE COMPOUNDS IN SITU
US5466646A (en) 1992-08-18 1995-11-14 Worcester Polytechnic Institute Process for the preparation of solid state materials and said materials
US5417956A (en) 1992-08-18 1995-05-23 Worcester Polytechnic Institute Preparation of nanophase solid state materials
NZ248813A (en) 1992-11-25 1995-06-27 Eastman Kodak Co Polymeric grinding media used in grinding pharmaceutical substances
US5346702A (en) 1992-12-04 1994-09-13 Sterling Winthrop Inc. Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization
US5298262A (en) 1992-12-04 1994-03-29 Sterling Winthrop Inc. Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
US5302401A (en) 1992-12-09 1994-04-12 Sterling Winthrop Inc. Method to reduce particle size growth during lyophilization
US5340564A (en) 1992-12-10 1994-08-23 Sterling Winthrop Inc. Formulations comprising olin 10-G to prevent particle aggregation and increase stability
US5336507A (en) 1992-12-11 1994-08-09 Sterling Winthrop Inc. Use of charged phospholipids to reduce nanoparticle aggregation
US5429824A (en) 1992-12-15 1995-07-04 Eastman Kodak Company Use of tyloxapole as a nanoparticle stabilizer and dispersant
US5352459A (en) 1992-12-16 1994-10-04 Sterling Winthrop Inc. Use of purified surface modifiers to prevent particle aggregation during sterilization
US5326552A (en) 1992-12-17 1994-07-05 Sterling Winthrop Inc. Formulations for nanoparticulate x-ray blood pool contrast agents using high molecular weight nonionic surfactants
DE4305003A1 (en) 1993-02-18 1994-08-25 Knoll Ag Process for the preparation of colloidal aqueous solutions of poorly soluble active substances
US5665383A (en) 1993-02-22 1997-09-09 Vivorx Pharmaceuticals, Inc. Methods for the preparation of immunostimulating agents for in vivo delivery
US5439686A (en) 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US5916596A (en) 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US5885486A (en) 1993-03-05 1999-03-23 Pharmaciaand Upjohn Ab Solid lipid particles, particles of bioactive agents and methods for the manufacture and use thereof
US5981719A (en) 1993-03-09 1999-11-09 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US6090925A (en) 1993-03-09 2000-07-18 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
FR2703927B1 (en) 1993-04-13 1995-07-13 Coletica Use of a transacylation reaction between an esterified polysaccharide and a polyamine to form in an aqueous medium a membrane at least on the surface of gelled particles.
US5576016A (en) 1993-05-18 1996-11-19 Pharmos Corporation Solid fat nanoemulsions as drug delivery vehicles
US5565215A (en) 1993-07-23 1996-10-15 Massachusettes Institute Of Technology Biodegradable injectable particles for imaging
US6596260B1 (en) 1993-08-27 2003-07-22 Novartis Corporation Aerosol container and a method for storage and administration of a predetermined amount of a pharmaceutically active aerosol
US5500161A (en) 1993-09-21 1996-03-19 Massachusetts Institute Of Technology And Virus Research Institute Method for making hydrophobic polymeric microparticles
CA2172513C (en) 1993-09-24 2008-01-08 Bernard A. Macleod Aminocyclohexylesters and uses thereof
SE9303574D0 (en) 1993-11-01 1993-11-01 Kabi Pharmacia Ab Composition for drug delivery and method of manufacturing thereof
WO1995013698A1 (en) 1993-11-15 1995-05-26 Zeneca Limited Microcapsules containing suspensions of biologically active compounds
US5468224A (en) 1993-11-30 1995-11-21 Souryal; Tarek O. Methods of color coding injectable medications
JP2699839B2 (en) 1993-12-03 1998-01-19 日本電気株式会社 Method for manufacturing semiconductor device
IE940292A1 (en) 1994-04-06 1995-10-18 Elan Corp Plc Biodegradable microcapsules and method for their manufacture
JP2865554B2 (en) 1994-04-08 1999-03-08 セントラル硝子株式会社 Gas chromatographic analysis of fluoromethyl-1,1,1,3,3,3-hexafluoroisopropyl ether
TW384224B (en) 1994-05-25 2000-03-11 Nano Sys Llc Method of preparing submicron particles of a therapeutic or diagnostic agent
FR2721510B1 (en) 1994-06-22 1996-07-26 Rhone Poulenc Rorer Sa Nanoparticles filterable under sterile conditions.
US5587143A (en) 1994-06-28 1996-12-24 Nanosystems L.L.C. Butylene oxide-ethylene oxide block copolymer surfactants as stabilizer coatings for nanoparticle compositions
GB9413202D0 (en) 1994-06-30 1994-08-24 Univ Bradford Method and apparatus for the formation of particles
US6007845A (en) 1994-07-22 1999-12-28 Massachusetts Institute Of Technology Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers
EP0783325B2 (en) 1994-09-27 2004-03-31 Amersham Health AS Contrast agent
US5720551A (en) 1994-10-28 1998-02-24 Shechter; Tal Forming emulsions
SE9403846D0 (en) 1994-11-09 1994-11-09 Univ Ohio State Res Found Small particle formation
DE4440337A1 (en) 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmaceutical nanosuspensions for drug application as systems with increased saturation solubility and dissolution rate
US5716642A (en) 1995-01-10 1998-02-10 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents using surface active material derived from similar pharmaceutical agents
US5560932A (en) 1995-01-10 1996-10-01 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents
US5662883A (en) 1995-01-10 1997-09-02 Nanosystems L.L.C. Microprecipitation of micro-nanoparticulate pharmaceutical agents
US5665331A (en) 1995-01-10 1997-09-09 Nanosystems L.L.C. Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers
US5569448A (en) 1995-01-24 1996-10-29 Nano Systems L.L.C. Sulfated nonionic block copolymer surfactants as stabilizer coatings for nanoparticle compositions
AU4862796A (en) 1995-02-06 1996-08-27 Nanosystems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5534270A (en) 1995-02-09 1996-07-09 Nanosystems Llc Method of preparing stable drug nanoparticles
US5518738A (en) 1995-02-09 1996-05-21 Nanosystem L.L.C. Nanoparticulate nsaid compositions
US5591456A (en) 1995-02-10 1997-01-07 Nanosystems L.L.C. Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer
US5573783A (en) 1995-02-13 1996-11-12 Nano Systems L.L.C. Redispersible nanoparticulate film matrices with protective overcoats
US5510118A (en) 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US5543133A (en) 1995-02-14 1996-08-06 Nanosystems L.L.C. Process of preparing x-ray contrast compositions containing nanoparticles
US5580579A (en) 1995-02-15 1996-12-03 Nano Systems L.L.C. Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers
AU4990696A (en) 1995-02-24 1996-09-11 Nanosystems L.L.C. Aerosols containing nanoparticle dispersions
US5605785A (en) 1995-03-28 1997-02-25 Eastman Kodak Company Annealing processes for nanocrystallization of amorphous dispersions
CA2216919C (en) 1995-03-28 2007-09-18 Fidia Advanced Biopolymers Srl Nanospheres comprising a biocompatible polysaccharide
IE75744B1 (en) 1995-04-03 1997-09-24 Elan Corp Plc Controlled release biodegradable micro- and nanospheres containing cyclosporin
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
SE9501384D0 (en) 1995-04-13 1995-04-13 Astra Ab Process for the preparation of respirable particles
GB9511220D0 (en) 1995-06-02 1995-07-26 Glaxo Group Ltd Solid dispersions
US5667809A (en) 1995-06-07 1997-09-16 Alliance Pharmaceutical Corp. Continuous fluorochemical microdispersions for the delivery of lipophilic pharmaceutical agents
FR2735978B1 (en) 1995-06-30 1997-09-19 Sanofi Sa PHARMACEUTICAL COMPOSITION OF AMIODARONE FOR PARENTERAL ADMINISTRATION
PT752245E (en) 1995-07-05 2002-09-30 Europ Economic Community BIOCOMPATIBLE AND BIODEGRADABLE NANOPARTICLES FOR THE ABSORPTION AND ADMINISTRATION OF PROTEINACEAL DRUGS
US6143211A (en) 1995-07-21 2000-11-07 Brown University Foundation Process for preparing microparticles through phase inversion phenomena
TW487582B (en) 1995-08-11 2002-05-21 Nissan Chemical Ind Ltd Method for converting sparingly water-soluble medical substance to amorphous state
CN1195990A (en) 1995-09-13 1998-10-14 日本新药株式会社 PGE1-containing freeze-dried preparation and process for production thereof
DE19545257A1 (en) 1995-11-24 1997-06-19 Schering Ag Process for the production of morphologically uniform microcapsules and microcapsules produced by this process
FR2742357B1 (en) 1995-12-19 1998-01-09 Rhone Poulenc Rorer Sa STABILIZED AND FILTRABLE NANOPARTICLES UNDER STERILE CONDITIONS
US6245349B1 (en) 1996-02-23 2001-06-12 éLAN CORPORATION PLC Drug delivery compositions suitable for intravenous injection
US5833891A (en) 1996-10-09 1998-11-10 The University Of Kansas Methods for a particle precipitation and coating using near-critical and supercritical antisolvents
US5637625A (en) 1996-03-19 1997-06-10 Research Triangle Pharmaceuticals Ltd. Propofol microdroplet formulations
IL117773A (en) 1996-04-02 2000-10-31 Pharmos Ltd Solid lipid compositions of coenzyme Q10 for enhanced oral bioavailability
US5660858A (en) 1996-04-03 1997-08-26 Research Triangle Pharmaceuticals Cyclosporin emulsions
EP0896815A4 (en) 1996-05-02 2000-02-09 Taisho Pharmaceutical Co Ltd Suspension of sparingly water-soluble acidic drug
ES2183172T3 (en) 1996-05-07 2003-03-16 Alkermes Inc PROCEDURE FOR THE PREPARATION OF MICROPARTICLES.
TR199801225T2 (en) 1996-05-20 1998-11-23 Janssen Pharmaceutica N.V. Antifungal compounds with enhanced bioavailability.
PL192560B1 (en) 1996-08-22 2006-11-30 Res Triangle Pharm Ltd Composition containing microparticles of water-insoluble substances and method of obtaining such compositions
US6344271B1 (en) 1998-11-06 2002-02-05 Nanoenergy Corporation Materials and products using nanostructured non-stoichiometric substances
DE19637517A1 (en) 1996-09-13 1998-03-19 Basf Ag Production of powdered, cold water dispersible carotenoid preparations and the use of the new carotenoid preparations
US6048550A (en) 1996-10-03 2000-04-11 Chan; Daniel C. F. Hydrophilic microparticles and methods to prepare same
US6261537B1 (en) 1996-10-28 2001-07-17 Nycomed Imaging As Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors
AU5374398A (en) 1996-12-17 1998-07-15 Cordant Technologies, Inc. Salting-out process of crystallizing 2,4,6,8,10,12-hexanitro-2,4,6,8,10,12-hexaazatetracyclo (5.5.0.05,903,11)-dodecane
US6458373B1 (en) 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US5874111A (en) 1997-01-07 1999-02-23 Maitra; Amarnath Process for the preparation of highly monodispersed polymeric hydrophilic nanoparticles
WO1998035666A1 (en) 1997-02-13 1998-08-20 Nanosystems Llc Formulations of nanoparticle naproxen tablets
US6045829A (en) 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
IT1292142B1 (en) 1997-06-12 1999-01-25 Maria Rosa Gasco PHARMACEUTICAL COMPOSITION IN THE FORM OF SOLID LIPID MICROPARTICLES SUITABLE FOR PARENTERAL ADMINISTRATION
KR19990001564A (en) 1997-06-16 1999-01-15 유충식 Azole antifungal agents with improved solubility and preparations containing them
US6217886B1 (en) 1997-07-14 2001-04-17 The Board Of Trustees Of The University Of Illinois Materials and methods for making improved micelle compositions
EP1011856B1 (en) 1997-08-05 2003-04-09 Microfluidics International Corporation Multiple stream high pressure mixer/reactor
DE19737481A1 (en) 1997-08-28 1999-03-04 Hoechst Ag Microparticles containing spherical linear polysaccharides
US6281175B1 (en) 1997-09-23 2001-08-28 Scimed Life Systems, Inc. Medical emulsion for lubrication and delivery of drugs
US5886239A (en) 1997-11-21 1999-03-23 Baxter International Inc. Method of preparing monofluoromethyl ethers
US6083514A (en) 1998-01-09 2000-07-04 Abbott Laboratories Polymethylpentene container for an inhalation anesthetic
US6086376A (en) 1998-01-30 2000-07-11 Rtp Pharma Inc. Dry aerosol suspension of phospholipid-stabilized drug microparticles in a hydrofluoroalkane propellant
EP1067914B1 (en) 1998-03-30 2006-02-22 Jagotec Ag Composition and method of preparing microparticles of water-insoluble substances
US6337092B1 (en) 1998-03-30 2002-01-08 Rtp Pharma Inc. Composition and method of preparing microparticles of water-insoluble substances
DK1071402T3 (en) 1998-04-09 2007-02-19 Hoffmann La Roche Process for Particles of (Sub) Micron Size by Dissolution in Compressed Gas and Surfactants
FR2777193B1 (en) 1998-04-14 2001-06-08 Coletica PARTICLE WITH A CHELATING HYDROXAMIC GROUP OF METAL IONS AND THEIR USE IN COSMETICS OR PHARMACY
WO1999059535A1 (en) 1998-05-15 1999-11-25 Unilever Plc Oral composition comprising capsules
US6696019B2 (en) 1998-06-15 2004-02-24 Bbi Bioseq, Inc. Rapid cryobaric sterilization and vaccine preparation
AU755993C (en) 1998-06-19 2003-10-30 Skyepharma Canada Inc. Processes to generate submicron particles of water-insoluble compounds
FR2780901B1 (en) 1998-07-09 2000-09-29 Coletica PARTICLES, IN PARTICULAR MICRO- OR NANOPARTICLES OF CROSSLINKED MONOSACCHARIDES AND OLIGOSACCHARIDES, THEIR PREPARATION METHODS AND COSMETIC, PHARMACEUTICAL OR FOOD COMPOSITIONS CONTAINING THE SAME
US6153225A (en) 1998-08-13 2000-11-28 Elan Pharma International Limited Injectable formulations of nanoparticulate naproxen
US6238677B1 (en) 1998-08-18 2001-05-29 The United States Of America As Represented By The Secretary Of Agriculture Starch microcapsules for delivery of active agents
US6165506A (en) 1998-09-04 2000-12-26 Elan Pharma International Ltd. Solid dose form of nanoparticulate naproxen
US6350786B1 (en) 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers
US8293277B2 (en) 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
US6375986B1 (en) 2000-09-21 2002-04-23 Elan Pharma International Ltd. Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
US6428814B1 (en) 1999-10-08 2002-08-06 Elan Pharma International Ltd. Bioadhesive nanoparticulate compositions having cationic surface stabilizers
SE9804001D0 (en) 1998-11-23 1998-11-23 Astra Ab New process
US6365191B1 (en) 1999-02-17 2002-04-02 Dabur Research Foundation Formulations of paclitaxel, its derivatives or its analogs entrapped into nanoparticles of polymeric micelles, process for preparing same and the use thereof
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6270806B1 (en) 1999-03-03 2001-08-07 Elan Pharma International Limited Use of peg-derivatized lipids as surface stabilizers for nanoparticulate compositions
US6267989B1 (en) 1999-03-08 2001-07-31 Klan Pharma International Ltd. Methods for preventing crystal growth and particle aggregation in nanoparticulate compositions
US6632443B2 (en) 2000-02-23 2003-10-14 National Research Council Of Canada Water-soluble compositions of bioactive lipophilic compounds
US6045826A (en) 1999-04-02 2000-04-04 National Research Council Of Canada Water-soluble compositions of bioactive lipophilic compounds
US6100302A (en) 1999-04-05 2000-08-08 Baxter International Inc. Propofol formulation with enhanced microbial characteristics
US6610317B2 (en) 1999-05-27 2003-08-26 Acusphere, Inc. Porous paclitaxel matrices and methods of manufacture thereof
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
KR100331529B1 (en) 1999-06-16 2002-04-06 민경윤 Composition for Oral Administration of Hardly Soluble Antifungal Agent and Process for the Preparation Thereof
US6458387B1 (en) 1999-10-18 2002-10-01 Epic Therapeutics, Inc. Sustained release microspheres
US20020048610A1 (en) 2000-01-07 2002-04-25 Cima Michael J. High-throughput formation, identification, and analysis of diverse solid-forms
US7338657B2 (en) 2001-03-15 2008-03-04 Biosphere Medical, Inc. Injectable microspheres for tissue construction
WO2001080828A2 (en) 2000-04-20 2001-11-01 Rtp Pharma Inc. Improved water-insoluble drug particle process
JP3412606B2 (en) 2000-08-04 2003-06-03 株式会社島津製作所 Laser diffraction / scattering particle size distribution analyzer
EP1355630B1 (en) 2000-08-15 2009-11-25 The Board Of Trustees Of The University Of Illinois Method of forming microparticles
US6635223B2 (en) 2000-10-25 2003-10-21 Andreas Maerz Method for inactivating micro-organisms using high pressure processing
ES2326209T3 (en) 2000-10-27 2009-10-05 Baxter Healthcare S.A. MICRO SPHERES PRODUCTION.
US7105176B2 (en) 2000-11-29 2006-09-12 Basf Aktiengesellschaft Production of solid preparations of water-soluble, sparingly water-soluble or water-insoluble active compounds
FR2817478A1 (en) 2000-12-04 2002-06-07 Oreal Aqueous suspension of nanospheres useful in cosmetic compositions, comprises an amorphous lipophilic active ingredient stabilized with a surfactant
DE10063712C1 (en) 2000-12-20 2002-08-29 Stiftung A Wegener Inst Polar Microbiological process for the biosynthesis of the natural blue-violet dyes violacein and deoxyviolacein and their use
US7193084B2 (en) 2000-12-22 2007-03-20 Baxter International Inc. Polymorphic form of itraconazole
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US20030072807A1 (en) 2000-12-22 2003-04-17 Wong Joseph Chung-Tak Solid particulate antifungal compositions for pharmaceutical use
US6977085B2 (en) 2000-12-22 2005-12-20 Baxter International Inc. Method for preparing submicron suspensions with polymorph control
US6607784B2 (en) 2000-12-22 2003-08-19 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US20030096013A1 (en) 2000-12-22 2003-05-22 Jane Werling Preparation of submicron sized particles with polymorph control
US6951656B2 (en) 2000-12-22 2005-10-04 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US20040256749A1 (en) 2000-12-22 2004-12-23 Mahesh Chaubal Process for production of essentially solvent-free small particles
US6884436B2 (en) 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
US20040022862A1 (en) 2000-12-22 2004-02-05 Kipp James E. Method for preparing small particles
TWI277414B (en) * 2001-01-12 2007-04-01 Baxter Int Esmolol formulation
US6310094B1 (en) 2001-01-12 2001-10-30 Baxter International Inc. Ready-to-use esmolol solution
US20040022861A1 (en) 2001-01-30 2004-02-05 Williams Robert O. Process for production of nanoparticles and microparticles by spray freezing into liquid
US20030054042A1 (en) 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
US20060003012A9 (en) 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
EP1429749A2 (en) 2001-09-26 2004-06-23 Baxter International Inc. Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal
US7112340B2 (en) 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
GB0204772D0 (en) 2002-02-28 2002-04-17 Phoqus Ltd Pharmaceutical dosage forms
FR2838969B1 (en) 2002-04-30 2006-05-19 Ellipse Pharmaceuticals METHOD FOR HIGH-PRESSURE STERILIZATION OF PHARMACEUTICAL COMPOSITIONS IN THE MICRO OR NANODISPERSEE FORM AND COMPOSITIONS THUS OBTAINED
EP1417962A1 (en) 2002-11-06 2004-05-12 AOP Orphan Pharmaceuticals AG Method for the manufacture of a medicament comprising esmolol
SE0203862L (en) 2002-12-20 2004-04-27 Tetra Laval Holdings & Finance Procedure for heat treatment of a package.
CN1753661A (en) * 2003-02-24 2006-03-29 美国诺华卡迪亚公司 Adenosine a1 receptor antagonist for the treatment of cardiac and renal diseases
US20040229901A1 (en) 2003-02-24 2004-11-18 Lauren Otsuki Method of treatment of disease using an adenosine A1 receptor antagonist
CA2524538A1 (en) 2003-05-19 2004-12-02 Baxter International Inc. Solid particles comprising an anticonvulsant or an immunosuppressive coated with one or more surface modifiers
JP4816083B2 (en) * 2003-08-08 2011-11-16 小野薬品工業株式会社 Heart rate reducing agent containing short-acting β-blocker as active ingredient
NZ549016A (en) 2004-02-13 2012-03-30 Bioavailability Inc A microemulsion preparation of high concentration propofol for anesthetic uses
EE05278B1 (en) 2004-03-23 2010-02-15 As Laser Diagnostic Instruments Method for Automatic Marking and Subsequent Identification of Liquids

Also Published As

Publication number Publication date
AU2008256949A1 (en) 2008-12-04
KR20100022992A (en) 2010-03-03
BRPI0811850A2 (en) 2014-11-18
JP2010528025A (en) 2010-08-19
US8722736B2 (en) 2014-05-13
MX2009012614A (en) 2009-12-11
WO2008147715A2 (en) 2008-12-04
CN101677943B (en) 2013-10-23
US20080293810A1 (en) 2008-11-27
WO2008147715A3 (en) 2009-05-22
EP2164464A2 (en) 2010-03-24
AU2008256949B2 (en) 2013-02-07
CN101677943A (en) 2010-03-24

Similar Documents

Publication Publication Date Title
JP5778384B2 (en) Esmolol formulation
RU2260429C2 (en) Sodium chloride-containing moxifloxacin compositions
CA2410446C (en) Esmolol formulation
US20150005376A1 (en) Concentrate esmolol
CN107810000B (en) Injectable pharmaceutical composition of leflunomide
AU2008256949B2 (en) Multi-dose concentrate esmolol with benzyl alcohol
EP2162154B1 (en) Colored esmolol concentrate
AU2014203121B2 (en) Concentrate esmolol
WO2022269572A1 (en) Pharmaceutical compositions

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20140515